PRESS RELEASE
News
-
-
PRESS RELEASE
Aperam - Résultats du troisième trimestre 2023: 'Le marché de l'acier inoxydable en crise, Alliages, Recyclage et Renouvelables donnent des résultats'
Aperam annonce une baisse des expéditions, de l'EBITDA ajusté et du bénéfice net pour l'année 2023, tout en faisant état de gains annualisés pour le quatrième trimestre 2023. Les perspectives pour le 1er trimestre 2024 restent prudentes malgré une légère amélioration du marché au quatrième trimestre 2023 -
-
PRESS RELEASE
Wenchang, Hainan Takes Flight as the Visionary 'City of the Future' Igniting a Thriving Aerospace Industry
Wenchang, China, is experiencing a surge in space-themed tourism, with the Long March-7 Y8 launch making it popular. The city has seen increased tourism, job creation, and economic growth due to its aerospace industry -
PRESS RELEASE
duPont REGISTRY Group Welcomes Colleen Cash as President of Sotheby's Motorsport and Chief Digital Officer of duPont REGISTRY Group
duPont REGISTRY Group and RM Sotheby's appoint Colleen Cash as President of Sotheby's Motorsport and Chief Digital Officer of duPont REGISTRY Group, creating a cohesive experience for both platforms, marking a significant milestone in duPont REGISTRY Group's commitment to elevating the luxury automotive marketplace -
-
PRESS RELEASE
Intellipharmaceutics International Inc. Announces Stock Option Grant
Intellipharmaceutics International Inc. issued 1,910,000 common share purchase options to certain eligible individuals under the stock option plan. The options vest over a period of 2 years and expire on February 5, 2034 -
-
PRESS RELEASE
Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
Applied DNA Sciences, Inc. (NASDAQ:APDN) announces Q1 fiscal year 2024 financial results and progress on GMP production capacity for mRNA therapeutics. Projects initial facility capacity to enable up to $15 million Linea IVT revenue annually -
PRESS RELEASE
Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting
Tryp Therapeutics, Inc. obtains interim court order for proposed arrangement with Exopharm Limited ACN 163 765 991. Meeting scheduled for March 8, 2024, in Toronto, Ontario, to vote on the arrangement resolution
